Aethlon Medical (NASDAQ: AEMD) is one of 23 public companies in the “Analytical instruments” industry, but how does it contrast to its competitors? We will compare Aethlon Medical to related companies based on the strength of its risk, institutional ownership, analyst recommendations, dividends, profitability, earnings and valuation.
Valuation & Earnings
This table compares Aethlon Medical and its competitors top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Aethlon Medical||$150,000.00||-$5.67 million||-2.20|
|Aethlon Medical Competitors||$1.08 billion||$109.59 million||25.08|
This is a breakdown of recent ratings and recommmendations for Aethlon Medical and its competitors, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Aethlon Medical Competitors||121||746||1100||53||2.54|
Aethlon Medical currently has a consensus target price of $3.00, indicating a potential upside of 197.03%. As a group, “Analytical instruments” companies have a potential upside of 2.50%. Given Aethlon Medical’s stronger consensus rating and higher probable upside, analysts clearly believe Aethlon Medical is more favorable than its competitors.
Insider and Institutional Ownership
7.4% of Aethlon Medical shares are held by institutional investors. Comparatively, 62.9% of shares of all “Analytical instruments” companies are held by institutional investors. 6.6% of Aethlon Medical shares are held by insiders. Comparatively, 14.7% of shares of all “Analytical instruments” companies are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
This table compares Aethlon Medical and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Aethlon Medical Competitors||-246.84%||-38.21%||-16.02%|
Volatility & Risk
Aethlon Medical has a beta of 2.04, suggesting that its stock price is 104% more volatile than the S&P 500. Comparatively, Aethlon Medical’s competitors have a beta of 1.20, suggesting that their average stock price is 20% more volatile than the S&P 500.
Aethlon Medical competitors beat Aethlon Medical on 8 of the 13 factors compared.
About Aethlon Medical
Aethlon Medical, Inc., a medical device company, focuses on creating devices that address unmet medical needs in health and biodefense worldwide. The company is developing Aethlon Hemopurifier, a clinical-stage therapeutic device that eliminates life-threatening viruses from the circulatory system of infected individuals. It is also involved in the development of exosomal biomarkers to diagnose and monitor life-threatening disease conditions, such as cancer and neurological disorders; and a therapeutic device to reduce the incidence of sepsis, a fatal bloodstream infection. The company was founded in 1991 and is based in San Diego, California.
Receive News & Ratings for Aethlon Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aethlon Medical and related companies with MarketBeat.com's FREE daily email newsletter.